ArticleCurrent oncology (Toronto, Ont.)2025
Venetoclax Plus CyBorD Induction Therapy and Venetoclax Maintenance Treatment for Immunoglobulin Light Chain Amyloidosis with t(11;14) Translocation.
Gréta Garami, Omar Obajed Al-Ali, István Virga, Anita Gulyás, Judit Bedekovics, István Tornai, Árpád Illés, Ferenc Magyari
Abstract readCase Reports
In one paragraphArticle in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Gréta GaramiDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Omar Obajed Al-AliDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
István VirgaDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Anita GulyásDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Judit BedekovicsDepartment of Pathology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.ORCID 0000-0002-9617-0156 István TornaiDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.ORCID 0000-0002-8163-101X Árpád IllésDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Ferenc MagyariDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.ORCID 0000-0002-2730-8668 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicImmunoglobulin Light-chain AmyloidosisSulfonamidesTranslocation, GeneticChromosomes, Human, Pair 11Chromosomes, Human, Pair 14CyclophosphamideHumansMaleMiddle AgedBridged Bicyclo Compounds, HeterocyclicCyclophosphamideSulfonamidesvenetoclax14) translocationautologous stem cell transplantationCyBorDdFLCimmunoglobulin-related/light chain amyloidosismaintenance treatmentplasma cell disordert(11venetoclax
Identifiers
PMID39996863
PMCPMC11854812
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390